Dossier assessment
Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
| Children from 3 years to < 12 years of age with chronic hepatitis C |
Result of dossier assessment:
| Genotype 1 and 4: hint of non-quantifiable added benefit; genotype 3, 5 and 6: added benefit not proven |
Project details
- Project no.
- A20-63
- Commission
- Commission awarded on 24.07.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Ledipasvir/sofosbuvir (hepatitis C) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed